Wednesday, April 23, 2025

Curia Appoints Steve Lavezoli as Vice President, Biologics

Related stories

GitLab and AWS Unveil GitLab Duo with Amazon Q to Revolutionize AI-Powered Software Development

GitLab, the most comprehensive AI-powered DevSecOps platform, has officially...

Scrut Automation Launches Scrut Teammates: AI-Powered GRC Agents Designed for Growth-Driven Enterprises

Scrut Automation, the company behind the next-generation Governance, Risk,...

Varonis and Pure Storage Join Forces to Deliver Industry-First Native Data Security Integration

Varonis Systems, has announced a strategic partnership with Pure...

Endace Integrates with Microsoft Sentinel for Deep Network Visibility

Packet capture authority Endace announced an integration between EndaceProbe and Microsoft...
spot_imgspot_img

Curia, a leading contract research, development and manufacturing organization, announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.

“This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb. “Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts. Under his guidance, I have every confidence that we will further our mission of life-changing life science.”

Also Read: Opentrons Announces Medical Robotics Expert Gregory Cole as Chief Innovation Officer to Accelerate AI-Driven Robo-Lab Partnerships and Innovations

Lavezoli most recently worked for Scorpius Biologics, a startup CDMO focused on microbial and mammalian biologics development and manufacturing as the vice president of commercial operations. Prior to joining Scorpius, he spent four years with Catalent Biologics, focused on drug substance business development in the U.S. for early-stage clinical programs and later focusing on late-stage commercial program integration. He also spent 12 years in the industrial gasses industry with Linde Gas before joining W.L. Gore in the startup biopharmaceutical division to work on a commercial business/market development role for bulk drug substance single-use items. He earned his B.S. in chemical engineering from Pennsylvania State University.

Curia holds a unique position in the CDMO industry with an impressive end-to-end offering,” said Lavezoli. “It’s an honor to join a team with such deep scientific expertise and values-driven purpose to drive a positive impact on patients’ lives.”

SOURCE: GlobeNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img